Kristen Lasseigne
Acute Care · Lafayette, LANPI 1912468083
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $714, 2.4 times the $297 reported in 2021.
Across 182 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Takeda Pharmaceuticals U.S.A., Inc.$399
- Pfizer$218
- Gilead$198
- Ardelyx, Inc.$180
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,01399%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $667 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $399 |
| Pfizer | 11 | $218 |
| Gilead | 6 | $198 |
| Ardelyx, Inc. | 9 | $180 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $172 |
| Johnson & Johnson(2 entities) | 7 | $166 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Intercept Pharmaceuticals, Inc. | 6 | $117 |
| Madrigal Pharmaceuticals | 4 | $108 |
| Phathom Pharmaceuticals, Inc. | 6 | $100 |
| Merck | 6 | $96 |
| Sanofi | 3 | $90 |
| Nestle Healthcare Nutrition Inc. | 5 | $74 |
| Bristol Myers Squibb | 4 | $61 |
| Ipsen Biopharmaceuticals, Inc | 3 | $57 |
| Braintree Laboratories, Inc. | 3 | $50 |
| QOL Medical, LLC | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Boston Scientific | 1 | $26 |
| Redhill Biopharma Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,031 in reported general payments places this provider in the 85th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 182 | $112,243 |
| XifaxanRifaximin | 21 | $64,272 |
| TrulancePlecanatide | 24 | $18,307 |
| Dexlansoprazole DrDexlansoprazole | 71 | $11,623 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 59 | $10,114 |
| MovantikNaloxegol Oxalate | 15 | $6,783 |
| Lubiprostone | 22 | $2,654 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 28 | $1,868 |
| Esomeprazole Magnesium | 116 | $1,734 |
| Sucralfate | 80 | $1,453 |
| Lansoprazole | 77 | $1,089 |
| Pantoprazole Sodium | 134 | $871 |
| Omeprazole | 93 | $838 |
| Dicyclomine Hcl | 37 | $538 |
| Colestipol Hcl | 14 | $535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $667 | $112,243182 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $172 | $82,58045 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $34 | $10,11459 claims |
| Redhill Biopharma Inc.Movantik | $14 | $6,78315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 acute care providers in Louisiana.
Other acute care in Lafayette
- Precious HodgesLafayette$70K
- Jeremy TerroLafayette$11K
- Kira WeberLafayette$5K
- Stepheny SumrallLafayette$2K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.